IL-38 | Jotup

Immunome Reports Second Quarter 2023 Financial Results

Retrieved on:

Wednesday, August 9, 2023

Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.

Key Points:

Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.
“We believe combining Immunome and Morphimmune’s technologies represents a major step in our long-term strategy of creating a preeminent oncology therapeutics company,” stated Purnanand Sarma, PhD, President and CEO of Immunome.
In June 2023, Immunome and Morphimmune , a private biotechnology company focused on developing targeted oncology therapeutics, announced that the two companies entered into a definitive merger agreement.
Cash and cash equivalents: As of June 30, 2023, cash and cash equivalents totaled $38.4 million.

Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity

Retrieved on:

Tuesday, May 23, 2023

The data in the article demonstrates that antibody-based targeting of IL-38 reactivates the immunostimulatory anti-tumor mechanisms within the tumor microenvironment in preclinical testing.

Key Points:

The data in the article demonstrates that antibody-based targeting of IL-38 reactivates the immunostimulatory anti-tumor mechanisms within the tumor microenvironment in preclinical testing.
“Although immune checkpoint inhibitors have transformed how we treat cancer, these therapies are only effective in a small subset of patients.
This highlights a significant need for continued innovation in this space,” said Matthew Robinson, Ph.D., Chief Technology Officer of Immunome.
We remain committed to leveraging the full power of our technology platform to continue advancing new and potentially transformative options for cancer patients.”

Immunome Reports Second Quarter 2022 Financial Results

Retrieved on:

Friday, August 5, 2022

COVID-19, Research, Infectious Diseases, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, Severe acute respiratory syndrome coronavirus 2, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, U.S. Securities and Exchange Commission, Fox Chase Cancer Center, Joint Program Executive Office Chemical and Biological Defense, Radiation, RNA transfection, Defense Health Agency, CEO, Omicron, Food, R, Forward-looking statement, SARS, Private Securities Litigation Reform Act, SEC, Cancer, Clinical trial, IND, IL-38, Research, Annual report, DOD, Patient, COVID-19, U.S. Department of Defense Strategy for Operating in Cyberspace, Infection, Therapy, Safety, G&A, Nature, Treatment, Contract, DHA, Goal, Nasdaq, IMM, Immune system, Defense, Disease, Pharmaceutical industry, Vaccine, Immunome, Chemical substance

Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.

Key Points:

Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.
We also presented data in the second quarter that demonstrated the retention of neutralizing activity against the BA.4/.5, and BA.2.12.1 subvariants of SARS CoV-2.
We look forward to reporting topline results from our Phase 1b study of IMM-BCP-01 in the second half of this year.
In July 2022, Immunome announced that its antibody cocktail retained activity against the BA.4/.5 and BA.2.12.1 subvariants in pseudovirus testing.

Immunome Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38

Retrieved on:

Monday, May 23, 2022

Preclinical research conducted by Immunome, and literature evidence1,2, suggests IL-38 dampens natural anti-tumor immune response.

Key Points:

Preclinical research conducted by Immunome, and literature evidence1,2, suggests IL-38 dampens natural anti-tumor immune response.
To help guide clinical development of IMM-ONC-01, Immunome conducted an extensive expression profile assessment of IL-38 mRNA using a proprietary commercial database of over 60 cancer sub-types established by Tempus Labs.
The results of this important assessment will allow us to better identify the patient populations most likely to respond to treatment with IMM-ONC-01 and streamline overall clinical development.
The Company will pursue additional partnerships as necessary to use this information and further refine its clinical development plan.

Immunome Reports Third Quarter 2021 Financial Results

Retrieved on:

Monday, November 15, 2021

Biotechnology, Infectious Diseases, Health, Pharmaceutical, Oncology, Joint Program Executive Office Chemical and Biological Defense, Safety, Manuscript, Cancer, G&A, Private Securities Litigation Reform Act, Defense, Clinical trial, Infection, R, CEO, Immune system, Disease, CDC, Food, Severe acute respiratory syndrome coronavirus 2, Goal, COVID-19, Research, Forward-looking statement, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Annual report, U.S. Department of Defense Strategy for Operating in Cyberspace, Phagocytosis, AACR, DHA, Conference, Therapy, U.S. Securities and Exchange Commission, Center, SEC, Program, Lambda, Contract, DOD, Centers for Disease Control and Prevention timeline, IL-38, BioRxiv, Nasdaq, Defense Health Agency, Patient, IL1RAPL1, Radiation, IND, Fine chemical, Vaccine, Air cargo

Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.

Key Points:

Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.
In September 2021, Immunome announced that its three-antibody cocktail (IMM-BCP-01) has demonstrated robust neutralizing activity against SARS-CoV-2 Lambda (C.37) and Delta AY.1/2 (Delta Plus) variants.
In October 2021, Immunome announced its submission of a preprint manuscript on its preclinical findings of its antibody cocktail, IMM-BCP-01, to bioRxiv.
(Contract number: W911QY-20-9-0019)
Research and development (R&D) expenses: R&D expenses for the three months ended September 30, 2021 were $4.5 million.

Immunome Presents Compelling Preclinical Data on Anti-IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on:

Thursday, October 7, 2021

The presentation highlighted that Immunomes antibody:

Key Points:

The presentation highlighted that Immunomes antibody:
Binds to human IL-38 and inhibits binding to its putative receptors, IL1RAPL1 and IL-36R.
Leads to inhibition of tumor growth in two different murine syngeneic tumor models treated with the antibody and induces protection following implantation of secondary tumors.
Our compelling preclinical data demonstrate the power of Immunome's platform to identify novel anti-tumor targets, such as IL-38.
Immunome is developing an anti-IL-38 antibody therapeutic designed to block human IL-38 and potentially provide clinical benefit in multiple cancers .